These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35165456)

  • 1. Structural basis for context-specific inhibition of translation by oxazolidinone antibiotics.
    Tsai K; Stojković V; Lee DJ; Young ID; Szal T; Klepacki D; Vázquez-Laslop N; Mankin AS; Fraser JS; Fujimori DG
    Nat Struct Mol Biol; 2022 Feb; 29(2):162-171. PubMed ID: 35165456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning.
    Wilson DN; Schluenzen F; Harms JM; Starosta AL; Connell SR; Fucini P
    Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13339-44. PubMed ID: 18757750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Context-specific inhibition of translation by ribosomal antibiotics targeting the peptidyl transferase center.
    Marks J; Kannan K; Roncase EJ; Klepacki D; Kefi A; Orelle C; Vázquez-Laslop N; Mankin AS
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12150-12155. PubMed ID: 27791002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.
    Skripkin E; McConnell TS; DeVito J; Lawrence L; Ippolito JA; Duffy EM; Sutcliffe J; Franceschi F
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3550-7. PubMed ID: 18663023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action.
    Xiong L; Kloss P; Douthwaite S; Andersen NM; Swaney S; Shinabarger DL; Mankin AS
    J Bacteriol; 2000 Oct; 182(19):5325-31. PubMed ID: 10986233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A noncanonical binding site of linezolid revealed via molecular dynamics simulations.
    Makarov GI; Makarova TM
    J Comput Aided Mol Des; 2020 Mar; 34(3):281-291. PubMed ID: 31832846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Putting the antibiotics chloramphenicol and linezolid into context.
    Crowe-McAuliffe C; Wilson DN
    Nat Struct Mol Biol; 2022 Feb; 29(2):79-81. PubMed ID: 35165457
    [No Abstract]   [Full Text] [Related]  

  • 8. Resistance to linezolid caused by modifications at its binding site on the ribosome.
    Long KS; Vester B
    Antimicrob Agents Chemother; 2012 Feb; 56(2):603-12. PubMed ID: 22143525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chemistry of peptidyltransferase center-targeted antibiotics: enzymatic resistance and approaches to countering resistance.
    McCusker KP; Fujimori DG
    ACS Chem Biol; 2012 Jan; 7(1):64-72. PubMed ID: 22208312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria.
    Leach KL; Swaney SM; Colca JR; McDonald WG; Blinn JR; Thomasco LM; Gadwood RC; Shinabarger D; Xiong L; Mankin AS
    Mol Cell; 2007 May; 26(3):393-402. PubMed ID: 17499045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for PoxtA-mediated resistance to phenicol and oxazolidinone antibiotics.
    Crowe-McAuliffe C; Murina V; Turnbull KJ; Huch S; Kasari M; Takada H; Nersisyan L; Sundsfjord A; Hegstad K; Atkinson GC; Pelechano V; Wilson DN; Hauryliuk V
    Nat Commun; 2022 Apr; 13(1):1860. PubMed ID: 35387982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Madumycin II inhibits peptide bond formation by forcing the peptidyl transferase center into an inactive state.
    Osterman IA; Khabibullina NF; Komarova ES; Kasatsky P; Kartsev VG; Bogdanov AA; Dontsova OA; Konevega AL; Sergiev PV; Polikanov YS
    Nucleic Acids Res; 2017 Jul; 45(12):7507-7514. PubMed ID: 28505372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes.
    Aoki H; Ke L; Poppe SM; Poel TJ; Weaver EA; Gadwood RC; Thomas RC; Shinabarger DL; Ganoza MC
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1080-5. PubMed ID: 11897593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis for Linezolid Binding Site Rearrangement in the
    Belousoff MJ; Eyal Z; Radjainia M; Ahmed T; Bamert RS; Matzov D; Bashan A; Zimmerman E; Mishra S; Cameron D; Elmlund H; Peleg AY; Bhushan S; Lithgow T; Yonath A
    mBio; 2017 May; 8(3):. PubMed ID: 28487427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis of translation inhibition by cadazolid, a novel quinoxolidinone antibiotic.
    Scaiola A; Leibundgut M; Boehringer D; Caspers P; Bur D; Locher HH; Rueedi G; Ritz D
    Sci Rep; 2019 Apr; 9(1):5634. PubMed ID: 30948752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center.
    Kloss P; Xiong L; Shinabarger DL; Mankin AS
    J Mol Biol; 1999 Nov; 294(1):93-101. PubMed ID: 10556031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the context-specific action of the classic peptidyl transferase inhibitor chloramphenicol.
    Syroegin EA; Flemmich L; Klepacki D; Vazquez-Laslop N; Micura R; Polikanov YS
    Nat Struct Mol Biol; 2022 Feb; 29(2):152-161. PubMed ID: 35165455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oxazolidinone class of drugs find their orientation on the ribosome.
    Wilson DN; Nierhaus KH
    Mol Cell; 2007 May; 26(4):460-2. PubMed ID: 17531804
    [No Abstract]   [Full Text] [Related]  

  • 19. On the structural basis of peptide-bond formation and antibiotic resistance from atomic structures of the large ribosomal subunit.
    Steitz TA
    FEBS Lett; 2005 Feb; 579(4):955-8. PubMed ID: 15680981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Update on the Structure of Oxazolidinone Analogs and a Comparison with Linezolid in Terms of In Vitro and Intracellular Efficacy against Clinically Relevant Bacterial Species.
    Tang Q; Zhao Y; Xu B; Gong P; Wang D
    Jpn J Infect Dis; 2017 Nov; 70(6):678-681. PubMed ID: 28890512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.